Russell Katie W, Rollins Michael D, Feola G Peter, Arnold Ryan, Barnhart Douglas C, Scaife Eric R
Division of Pediatric Surgery, University of Utah, Primary Children's Medical Center, Salt Lake City, Utah, United States.
Pediatric Interventional Radiology, University of Utah, Primary Children's Medical Center, Salt Lake City, Utah, United States.
Eur J Pediatr Surg. 2014 Aug;24(4):317-21. doi: 10.1055/s-0033-1349058. Epub 2013 Jul 11.
Sclerotherapy is well described as a treatment for lymphatic malformations (LMs) in the head, neck, and other soft tissue areas. This study aims to evaluate the effectiveness of intralesional sclerotherapy as primary treatment for intra-abdominal LMs in children.
We conducted a retrospective review from 2008 to 2012 of all children with intra-abdominal LMs treated with sclerotherapy at our tertiary children's hospital.
In this study, five patients underwent sclerotherapy as a primary intervention for intra-abdominal LMs. The ages of these patients ranged from 12 to 52 months at the time of initial treatment. Doxycycline was used as the primary sclerotherapy agent. The patients required between three and five (median 3) sclerosing treatments over a period that ranged from 5 to 366 days (median 28). No child has required an operation and all LMs have decreased in size. The median decease in maximum diameter is 62% (21-67). Complete resolution has not been attained but all have experienced symptomatic relief with a median follow-up of 3 (1-24) months.
Sclerotherapy is an effective first-line therapy for intra-abdominal LMs in the pediatric population and should be considered when treating these difficult lesions.
硬化疗法作为头颈部及其他软组织区域淋巴管畸形（LM）的一种治疗方法已有详尽描述。本研究旨在评估病灶内硬化疗法作为儿童腹内LM主要治疗方法的有效性。
我们对2008年至2012年期间在我们的三级儿童医院接受硬化疗法治疗的所有腹内LM患儿进行了回顾性研究。
在本研究中，5例患者接受了硬化疗法作为腹内LM的主要干预措施。这些患者在初次治疗时年龄为12至52个月。强力霉素被用作主要的硬化治疗剂。患者在5至366天（中位数28天）的时间内需要进行三至五次（中位数3次）硬化治疗。没有儿童需要进行手术，所有LM的大小均有所减小。最大直径的中位数减小了62%（21%-67%）。虽未实现完全消退，但在中位随访3个月（1-24个月）时所有患者症状均得到缓解。
硬化疗法是儿科人群腹内LM的一种有效一线治疗方法，在治疗这些难治性病变时应予以考虑。
